Naia Pharmaceuticals builds, funds and manages new biotech companies which develop much-needed therapeutics effectively, efficiently and in proximity to target markets.
What do we do?
Naia is funding and developing companies that address regional and global unmet medical needs in various markets with an initial focus on metabolic and rare diseases.
In selecting drug candidates, Naia focuses on those that have a potential impact on unmet medical need; and the scientific merit and ability to rapidly achieve clinical proof-of-concept while increasing asset value at lower risk and cost.
Naia operates its subsidiaries as a single organization for operating purposes, thus saving time and money in development. Further savings are achieved by operating as a virtual company, using proven contract research organizations (CROs) and other contract organizations to manage its operations.
Using creative in-licensing and leveraging cross-border arbitrage (different regions value the same program differently), Naia is able to identify new opportunities quickly. The team’s worldwide network and Cayman Islands structure allows for programs to be developed and commercialized where they are most needed, creating instant arbitrage value.
While Naia targets drug development in emerging markets where the demand for branded drug opportunities is large, such as in the Middle East, Latin America and Asia Pacific, it also takes advantage of strategic opportunities in developed markets.
How do we do it?
Naia’s unique operating structure allows implementation of a focused global strategy. This approach allows Naia to source, finance, develop and commercialize drugs efficiently and effectively.
Naia’s operating structure includes a Cayman Island-based holding company, a US based agent management company and several subsidiaries that focus on development activities of like assets.
This shared infrastructure and management team leads to increase efficiency in drug development at significant savings.
The holding companies have and will have operations in multiple locations, depending on market needs, including in Hong Kong, Ireland, Singapore, the United Kingdom and the United States.
Naia’s Global Advisory Network provides subsidiaries, access to the world’s leading scientific, medical and business advisors for advice, access and introductions.
Naia’s Cayman Islands-Based holding Company consolidates overhead costs across the model and allows seamless international transfer of intellectual property.
Naia’s Operating Entities are strategically located in targeted localities according to development needs.
Strategic Drug Development
Naia is pursuing niche regional opportunities for development and out-licensing of drug candidates to align with urgency on the part of local payers, health authorities and potential commercial partners, ensuring efficient, focused and cost-effective development.
For example, Naia will target regionally-specific commercial deals where the demand for branded drugs opportunities is large, such as in the Middle East, Latin America and Asia Pacific.
Naia can tailor an asset to a specific geography where the disease is prevalent and the unmet need is highest. Naia also will take advantage of strategic opportunities in developed markets.
Naia’s approach to identifying and selecting opportunities.
In selecting drug candidates, Naia focuses on those that have a potential impact on unmet medical need and the scientific merit and ability to rapidly achieve clinical proof-of-concept while increasing asset value at lower risk and cost.
Identify innovative drug development opportunities …
Drug candidates that have been “shelved” due to a reprioritization of pipelines or strategic constraints.
Drug candidates under-appreciated in their current markets.
Drug candidates from biotech companies seeking to diversify.
Drug candidates that can be repositioned due to new scientific information.
Select drug candidates to evaluate based on …
Potential impact on unmet medical need.
Scientific merit and ability to rapidly achieve clinical proof-of-concept in select patient populations.
Opportunity to increase asset value at lower risk and cost.
Ability to develop in emerging markets.
Opportunity to achieve high investment return.